EA009068B1 - Ингаляционная композиция в виде раствора с солью тиотропия - Google Patents

Ингаляционная композиция в виде раствора с солью тиотропия Download PDF

Info

Publication number
EA009068B1
EA009068B1 EA200300483A EA200300483A EA009068B1 EA 009068 B1 EA009068 B1 EA 009068B1 EA 200300483 A EA200300483 A EA 200300483A EA 200300483 A EA200300483 A EA 200300483A EA 009068 B1 EA009068 B1 EA 009068B1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition according
drug composition
tiotropium
active substance
inhaler
Prior art date
Application number
EA200300483A
Other languages
English (en)
Russian (ru)
Other versions
EA200300483A1 (ru
Inventor
Карин Дрексель
Барбара Никлаус-Хумке
Кристель Шмельцер
Петра Барт
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA009068(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200300483A1 publication Critical patent/EA200300483A1/ru
Publication of EA009068B1 publication Critical patent/EA009068B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200300483A 2000-10-31 2001-10-24 Ингаляционная композиция в виде раствора с солью тиотропия EA009068B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10054042 2000-10-31
PCT/EP2001/012296 WO2002036591A2 (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz

Publications (2)

Publication Number Publication Date
EA200300483A1 EA200300483A1 (ru) 2003-12-25
EA009068B1 true EA009068B1 (ru) 2007-10-26

Family

ID=7661727

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300483A EA009068B1 (ru) 2000-10-31 2001-10-24 Ингаляционная композиция в виде раствора с солью тиотропия

Country Status (32)

Country Link
EP (1) EP1335729A2 (cs)
JP (1) JP4559703B2 (cs)
KR (1) KR100983208B1 (cs)
CN (1) CN1237970C (cs)
AR (1) AR038765A1 (cs)
AU (2) AU2174102A (cs)
BG (1) BG66425B1 (cs)
BR (1) BR0115016A (cs)
CA (1) CA2427583C (cs)
CZ (1) CZ305033B6 (cs)
DE (1) DE10152369A1 (cs)
EA (1) EA009068B1 (cs)
EC (1) ECSP034570A (cs)
EE (1) EE05343B1 (cs)
HR (1) HRP20030337A2 (cs)
HU (1) HUP0301377A3 (cs)
IL (2) IL155676A0 (cs)
ME (1) ME00242B (cs)
MX (1) MXPA03003750A (cs)
MY (1) MY132777A (cs)
NO (1) NO332524B1 (cs)
NZ (1) NZ526024A (cs)
PE (1) PE20020518A1 (cs)
PL (1) PL361001A1 (cs)
SA (1) SA01220503B1 (cs)
SK (1) SK288031B6 (cs)
TW (1) TWI296934B (cs)
UA (1) UA76435C2 (cs)
UY (1) UY26991A1 (cs)
WO (1) WO2002036591A2 (cs)
YU (1) YU33103A (cs)
ZA (1) ZA200303045B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1652926T3 (da) 2000-04-28 2010-02-15 Kosan Biosciences Inc Krystallinsk epothilon D
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1677778A2 (en) * 2003-10-09 2006-07-12 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
AU2006224842B2 (en) * 2005-03-16 2011-09-29 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
JP2009538361A (ja) * 2006-05-26 2009-11-05 デイ・リミテッド・パートナーシップ ４級アンモニウムムスカリン受容体アンタゴニストの噴霧可能組成物
CN100446770C (zh) * 2007-01-10 2008-12-31 上海现代药物制剂工程研究中心有限公司 丙酸培氯米松水雾剂
TR200907237A2 (tr) * 2009-09-23 2011-04-21 B�Lg�� Mahmut Tiotropyum kuru toz kombinasyonu
CN116173025A (zh) * 2018-07-26 2023-05-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN116196298A (zh) * 2018-07-26 2023-06-02 四川海思科制药有限公司 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A2 (de) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmazeutische Aerosolformulierungen
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT835098E (pt) * 1995-06-27 2002-12-31 Boehringer Ingelheim Pharma Nova composicao farmaceutica estavel para a producao de aerossois sem gas propulsante
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0504112A2 (de) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmazeutische Aerosolformulierungen
DE4203306A1 (de) * 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh Asthma oder pulmonal-aerosolzubereitungen mit lecithin
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
JPH10298107A (ja) * 1997-04-25 1998-11-10 Taisho Pharmaceut Co Ltd 医薬組成物
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BALZANO G. ET AL.: "Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients. with chronic airflow obstruction: metered dose inhaler versus jet nebulizer", JOURNAL OF AEROSOL MEDICINE: THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE. UNITED STATES 2000 SPRING, vol. 13, no. 1, April 2000 (2000-04), pages 25-33, XP001078735, ISSN: 0894-2684, page 26, column 2, paragraph 1 page 26, column 2, paragraph 3 page 27, column 2, paragraph 2 *
MON F. ET AL.: "AEROSOL THERAPY IN ASTHMA", REVUE DES MALADIES RESPIRATOIRES, vol. 6, no. 3, 1989, pages 189-200, XP001078722, ISSN: 0761-8425, Tab. IV page 196, Tab. V page 197 page 196, column 2, line 25 page 197, column 2 *
NACLERIO R.M.: "Optimizing treatment options." CLINICAL AND EXPERIMENTAL ALLERGY, vol. 28, no. SUPPL. 6, December 1998 (1998-12), pages 54-59, XP001078789, ISSN: 0954-7894, page 55, column 2, paragraph 1 page 55, column 2, paragraph 3 page 56, column 1 - column 2, paragraph 1 letzter Satz page 56, column 2, paragraph 3 page- 55, column 2 Absatz ??ber Spalter 1 und 2 hinweg, page 56 *
NISHIMURA KOICHI ET AL.: "Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma". ALLERGOLOGY INTERNATIONAL, vol. 48, no. 1, March 1999 (1999-03), pages 85-88, XP001070756, ISSN: 1323-8930, "Discussion", page 87, column 1, "Abstract", page 85, column 1, "Study protocol", page 85, column 1, "Results", page 86, column 2 *
PATENT ABSTRACTS OF JAPAN, vol. 1999, no. 02, 26 February 1999 (1999-02-26) & JP 10 298107 A (TAISHO PHARMACEUT CO LTD.), 10 November 1998 (1998-11-10), abstract *
PAVIA D. ET AL.: "Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler", JOURNAL OF AEROSOL MEDICINE: THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE. UNITED STATES 1999, vol. 12 Suppl 1, 1999, pages S33-S39, XP001078739, ISSN: 0894-2684, page 34, column 1, paragraph 2 page 35, column 2, line 2 page 36, column 2, paragraph 2 page 37, column 1, paragraph 2 *
RUTGERS S.R. ET AL.: "Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. UNITED STATES MAR 1998, vol. 157, no. 3, Pt. 1, March 1998 (1998-03), pages 880-886, XP001078742, ISSN: 1073-449X, page 881, column 1, paragraph 1 page 885, column 1, paragraph 5 -column 2, paragraph 1 page 881; figure 1 *
VAN SCHAYCK C.P. ET AL.: "Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible?", JAMA: THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. UNITED STATES 12 JUL 1995, vol. 274, no. 2, 12 July 1995 (1995-07-12), pages 161-164, XP001078744, ISSN: 0098-7484, "Interventions", page 161, column 1 *

Also Published As

Publication number Publication date
MXPA03003750A (es) 2004-10-15
PL361001A1 (en) 2004-09-20
UY26991A1 (es) 2002-06-20
BR0115016A (pt) 2005-05-03
AU2002221741B2 (en) 2007-04-05
JP2004523482A (ja) 2004-08-05
ECSP034570A (es) 2003-06-25
CA2427583A1 (en) 2002-05-10
BG66425B1 (bg) 2014-04-30
WO2002036591A2 (de) 2002-05-10
KR100983208B1 (ko) 2010-09-20
SK5262003A3 (en) 2003-10-07
PE20020518A1 (es) 2002-07-12
IL155676A (en) 2012-05-31
NO332524B1 (no) 2012-10-08
HUP0301377A2 (hu) 2003-10-28
BG107726A (bg) 2004-11-30
ZA200303045B (en) 2004-04-22
CZ305033B6 (cs) 2015-04-08
NO20031914D0 (no) 2003-04-29
TWI296934B (en) 2008-05-21
CN1473044A (zh) 2004-02-04
AR038765A1 (es) 2005-01-26
EP1335729A2 (de) 2003-08-20
MEP40708A (en) 2011-02-10
ME00242B (me) 2011-05-10
JP4559703B2 (ja) 2010-10-13
SK288031B6 (sk) 2012-12-03
HK1060569A1 (en) 2004-08-13
HRP20030337A2 (en) 2005-04-30
NO20031914L (no) 2003-06-23
NZ526024A (en) 2005-10-28
EE05343B1 (et) 2010-10-15
YU33103A (sh) 2006-05-25
EA200300483A1 (ru) 2003-12-25
AU2174102A (en) 2002-05-15
SA01220503B1 (ar) 2007-03-10
MY132777A (en) 2007-10-31
CZ20031487A3 (cs) 2003-09-17
DE10152369A1 (de) 2002-05-08
UA76435C2 (en) 2006-08-15
WO2002036591A3 (de) 2002-07-25
CN1237970C (zh) 2006-01-25
EE200300202A (et) 2003-10-15
KR20040010552A (ko) 2004-01-31
CA2427583C (en) 2008-02-12
HUP0301377A3 (en) 2005-12-28
IL155676A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
US6890517B2 (en) Inhalable formulation of a solution containing a tiotropium salt
AU2004275490B2 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
US20040176338A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
US20020111363A1 (en) Inhalable formulation of a solution containing a tiotropium salt
PL205330B1 (pl) Wolny od propelentu aerozolowy roztwór do inhalacji zawierający sól tiotropium oraz zastosowanie roztworu
JP2004512359A (ja) 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
US20110038806A1 (en) Medicaments for inhalation comprising an anticholinergic and a steroid
US20040102469A1 (en) Method for reducing the mortality rate
EA009068B1 (ru) Ингаляционная композиция в виде раствора с солью тиотропия
PL211227B1 (pl) Kompozycja farmaceutyczna zawierająca środek przeciwcholinergiczny i steroid oraz zastosowanie kompozycji
EA007228B1 (ru) Аэрозольная композиция для ингаляции, содержащая соль тиотропия
RU2361586C2 (ru) Комбинация из антихолинергического средства и стероида и ее применение для лечения заболеваний дыхательных путей путем ингаляции
US20060110329A1 (en) Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid
EA007604B1 (ru) Ингаляционная композиция в виде раствора с солью тиотропия
US20060110330A1 (en) Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid
US20050059643A1 (en) Medicaments for inhalation comprising a steroid and a betamimetic

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): BY RU